^{_{Welcome to the TraderTV Live Morning Research Note. Here's what's making major moves in the market today.}}

0830 - GDP growth rate q/q (final) for Q3: Expected 2.8%; Prior 2.8%
0830 - GDP price index (final) for Q3: Expected 1.9%; Prior 1,.9%
0830 - Initial jobless claims: Expected 230k; Prior 242k
1000 - Existing home sales for November: Expected 4.09M; Prior 3.96M

Micron Technology Inc (MU)

-12.54%

Gapping down following its earnings report for Q1 2025. Adjusted earnings of $1.79 per share exceeded estimates of $1.76 per share, while sales of $8.709 billion missed estimates of $8.721 billion. Micron’s adjusted cash flow and operating cash flow both dropped on a quarterly basis. The company guided Q2 revenue of $7.7 billion to $8.1 billion and adjusted earnings of $1.33-$1.53 per share, missing estimates of $9 billion and $1.92, respectively.

Tesla Inc (TSLA)

+3.29%

Trading higher premarket after Bloomberg reported that the company is in preliminary discussions with Austin authorities about safety expectations for its autonomous vehicle technology, with communication dating back to May. CEO Elon Musk previously announced plans to launch driverless ride-hailing services in California and Texas in 2024. Separately, data from the European Automobile Manufacturers’ Association indices that Tesla’s new vehicle registrations in the EU fell by 41% year-over-year in November, contributing to a 15% decline for the year-to-date.

NVIDIA Corp and Apple Inc

+0.89%

The companies have collaborated to integrate Apple's Recurrent Drafter (ReDrafter) text generation technique into NVIDIA TensorRT-LLM, significantly accelerating large language model performance. This integration, as discussed in a blog post by Apple researchers. delivers up to 2.7x faster token generation on NVIDIA GPUs, reducing latency and computational costs for production applications. Apple is flat on the day, and Nvidia is trading higher premarket.

NVDA, AAPL

Palantir Technologies Inc (PLTR)

+2.75%

Trading higher premarket after edxtending its partnership with the U.S. Army to provide the Army Vantage data analytics platform, supporting the Army Data Platform initiative. The agreement is valued at $400.74 million over up to four years, with a total available ceiling of $618.87 million.

Alphabet Inc (GOOGL)

+1.46%

Trading higher premarket after Waymo, Alphabet Inc.'s autonomous driving unit, reported over four million fully autonomous rides in 2024. This number brings Waymo’s total to more than five million rides, with services available in Phoenix, Los Angeles, and San Francisco. Waymo plans to expand to Austin and Atlanta via the Uber app in 2025, launch in Miami in 2026, and begin international testing in Tokyo with all-electric Jaguar I-PACEs in early 2025.

Crypto Stocks

+2.92%

Trading higher premarket in tandem with a recovery in Bitcoin, which sold off along with the rest of the market during Fed Chair Jerome Powell’s press conference on Wednesday. The cryptocurrency closed just above $100,000 on Wednesday and broke below the $99,000 level on Thursday morning before reclaiming $102,000.

IBIT, MARA, ETHE, CION RIOT, CLSK, MSTR, BTBT, HIVE, CAN

Quantum Stocks

-3.34%

Trading lower as a group with strong premarket volume. The group has been trading sharply higher since the election of Donald Trump as US President, and the rally accelerated when Google announced its quantum chip. Quantum Computing (QUBT) was singled out in a negative note from Citron Research on Wednesday morning, with Rigetti and IONQ also being singled out in the note; Rigetti was singled out in a separate note from Citron a week earlier.

QUBT, RGTI, IONQ, QSI, QBTS

C3.ai Inc (AI)

-2.72%

Trading lower premarket following a downgrade from Keybanc. The analyst lowered its rating on the company from Sector Perform to Underweight and set a $29 price target for the stock.

Bio-Path Holdings Inc (BPTH)

+127.19%

Gapping up after announcing promising preclinical results for BP1001-A as a potential treatment for obesity in Type 2 diabetes patients. The treatment aims to improve insulin sensitivity, addressing a key issue in managing the condition.